Morgan Stanley raised the firm’s price target on AstraZeneca to 13,400 GBp from 12,900 GBp and keeps an Overweight rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AIM ImmunoTech announces open enrollment for Phase 1b/2 study of Ampligen
- Absci appoints Sir Pangalos to its board of directors
- AstraZeneca put volume heavy and directionally bearish
- Compugen to receive $10M milestone payment from AstraZeneca
- Zura Bio names Robert Lisicki as COO, Kiran Nistala as CMO